Survival of Civilian and Prisoner Drug-Sensitive, Multi- and Extensive Drug- Resistant Tuberculosis Cohorts Prospectively Followed in Russia
Open Access
- 10 June 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (6) , e20531
Abstract
A long-term observational study was conducted in Samara, Russia to assess the survival and risk factors for death of a cohort of non-multidrug resistant tuberculosis (non-MDRTB) and multidrug resistant tuberculosis (MDRTB) civilian and prison patients and a civilian extensive drug-resistant tuberculosis (XDRTB) cohort. MDRTB and XDRTB rates of 54.8% and 11.1% were identified in the region. Half (50%) of MDRTB patients and the majority of non-MDRTB patients (71%) were still alive at 5 years. Over half (58%) of the patients died within two years of establishing a diagnosis of XDRTB. In the multivariate analysis, retreatment (HR = 1.61, 95%CI 1.04, 2.49) and MDRTB (HR = 1.67, 95%CI 1.17, 2.39) were significantly associated with death within the non-MDR/MDRTB cohort. The effect of age on survival was relatively small (HR = 1.01, 95%CI 1.00, 1.02). No specific factor affected survival of XDRTB patients although median survival time for HIV-infected versus HIV-negative patients from this group was shorter (185 versus 496 days). The majority of MDRTB and XDRTB strains (84% and 92% respectively) strains belonged to the Beijing family. Mutations in the rpoB (codon 531 in 81/92; 88.8%), katG (mutation S315T in 91/92, 98.9%) and inhA genes accounted for most rifampin and isoniazid resistance respectively, mutations in the QRDR region of gyrA for most fluroquinolone resistance (68/92; 73.5%). Alarmingly high rates of XDRTB exist. Previous TB treatment cycles and MDR were significant risk factors for mortality. XDRTB patients' survival is short especially for HIV-infected patients. Beijing family strains comprise the majority of drug-resistant strains.Keywords
This publication has 33 references indexed in Scilit:
- Outcome of hospitalized MDR-TB patients: Israel 2000–2005European Journal of Clinical Microbiology & Infectious Diseases, 2010
- Extensively Drug-resistant Tuberculosis: Epidemiology and Management ChallengesInfectious Disease Clinics of North America, 2010
- Follow-Up of Patients with Multidrug Resistant Tuberculosis Four Years after Standardized First-Line Drug TreatmentPLOS ONE, 2010
- Tuberculosis control and elimination 2010–50: cure, care, and social developmentThe Lancet, 2010
- Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004European Respiratory Journal, 2010
- Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectivesCurrent Opinion in Pulmonary Medicine, 2010
- HIV Coinfection in Multidrug- and Extensively Drug-Resistant Tuberculosis Results in High Early MortalityAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Discriminatory Ability of Hypervariable Variable Number Tandem Repeat Loci in Population-based Analysis of Mycobacterium tuberculosis Strains, London, UKEmerging Infectious Diseases, 2009
- MDR-TB and XDR-TB: drug resistance and treatment outcomes: Table 1—European Respiratory Journal, 2009
- Evaluation of the Epidemiologic Utility of Secondary Typing Methods for Differentiation ofMycobacterium tuberculosisIsolatesJournal of Clinical Microbiology, 2003